Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects

Melanoma is one of the most common malignant tumors. The anti-PD-1 antibody is used for the treatment of metastatic melanoma. Treatment success is only 35–40% and a range of immune-related adverse reactions can occur. Combination of anti-PD1 antibody therapy with other oncology therapies has been at...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xixi, Zhu, Shunyao, Yin, Ping, Zhang, Shuangshuang, Xu, Juewen, Zhang, Qin, Shi, Senlin, Zhang, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439241/
https://www.ncbi.nlm.nih.gov/pubmed/34515617
http://dx.doi.org/10.1080/10717544.2021.1971797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439241/
https://www.ncbi.nlm.nih.gov/pubmed/34515617
http://dx.doi.org/10.1080/10717544.2021.1971797

Ejemplares similares